Discovering novelty in sequential patterns: application for analysis of microarray data on Alzheimer disease.
Sandra Bringay1, Mathieu Roche, Maguelonne Teisseire
1Laboratory of Informatics, University of Montpellier 2, Montpellier, France.
Studies in Health Technology and Informatics
|September 16, 2010
Summary
The NoDisco method enhances microarray data analysis by identifying novel gene sequences. This approach helps researchers focus on relevant biological information, improving discovery in complex datasets like those for Alzheimer's disease.
Area of Science:
- Bioinformatics
- Genomics
- Data Mining
Background:
- Microarray data analysis presents challenges due to excessive irrelevant results from existing methods.
- Discovering novelties in gene sequences from microarray data requires advanced techniques.
Purpose of the Study:
- To introduce a novel method, NoDisco, for identifying significant gene sequences within microarray data.
- To improve the efficiency and relevance of gene sequence discovery in biological research.
Main Methods:
- NoDisco identifies 'popular' genes (literature-cited) and 'innovative' genes (linked to popular but not cited).
- The method also identifies popular and innovative gene sequences.
- Biologists can select relevant sequences and retrieve top-k documents for context.
Main Results:
- The efficiency of the NoDisco method was demonstrated using real-world data.
- The method was applied to microarray data related to Alzheimer's disease mechanisms.
Conclusions:
- Sequence selection based on popularity and innovation aids experts in focusing on pertinent findings.
- Retrieving top-k documents enhances the understanding of selected gene sequences.
More Related Videos
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...